Sangamo BioSciences, Inc. Reports Second Quarter 2013 Financial Results

... to our preclinical programs partially offset by lower clinical trial and manufacturing expenses for our SB-728-T HIV/AIDS program. General and administrative expenses were , at the 16th Annual Meeting of the American Society of Gene and Cell Therapy ...

http://www.biospace.com/news_story.aspx?StoryID=303692&full=1